Biotech

NeuralAnalytics

NeuralAnalytics Raises $100M Series B to Transform Biotech

$100M Series B
Total Raised
Series
Latest Round
2021
Founded
100-250
Employees
Washington, DC
1 min read

Quick Facts

Valuation
$750M
Latest Round Size
$100M Series B
Latest Round Date
October 2025

NeuralAnalytics Raises $100M Series B in Latest Funding Round

NeuralAnalytics has successfully closed a $100M Series B funding round, marking a significant milestone in the company's growth trajectory. The round was led by Kleiner Perkins, with participation from 500 Startups.

Company Overview

Founded in 2021 and headquartered in Washington, DC, NeuralAnalytics has established itself in the Biotech space. Leading artificial intelligence infrastructure enabling scalable ML deployment for businesses

With a current valuation of $750M, the company has demonstrated strong market traction and investor confidence.

Investment Details

  • Amount Raised: $100M Series B
  • Valuation: $750M
  • Lead Investor: Kleiner Perkins

Future Outlook

As NeuralAnalytics moves forward with its expanded funding, the company is well-positioned to capitalize on market opportunities and drive innovation in the biotech space.

Key Investors

Kleiner Perkins
Venture Capital
Leading venture capital firm investing in technology companies
500 Startups
Venture Capital
Leading venture capital firm investing in technology companies

About the Author

Michael Torres
Michael Torres
Former startup founder turned investment analyst, focusing on early-stage technology and consumer companies.